On October 21, 2026 Foundation Medicine, Inc., a global, patient-focused precision medicine company, reported the acceptance of 12 abstracts for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, scheduled for October 23-27, 2026, in Madrid, Spain. These presentations cover key topics such as MTAP loss, the clinical impact of clonal hematopoiesis (CH), and the expanded utility of circulating tumor DNA (ctDNA) tumor fraction.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to 10 poster presentations, Foundation Medicine’s research will be featured in two Rapid Oral Sessions:

2218RO – Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3
2219RO – Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)
Friday, October 23 at 13:00 CEST in Bilbao Auditorium – Hall 3
Foundation Medicine will also host a series of expert-led booth talks in its booth 1030 in Hall 10:

Saturday, October 24
13:00 – 13:15 CEST – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
13:25 – 13:40 CEST – Breaking the Sensitivity Floor: The Science of Ultra-Sensitive MRD
13:50 – 14:05 CEST – Detect MTAP Loss More Often in Your Clinical Trials: Don’t Miss the Signal
14:15 – 14:30 CEST – Don’t Miss Fusions and Complex Variants with FoundationOneRNA
Sunday, October 25
13:00 – 13:15 CET – Translating Ultra-Sensitive MRD to Clinical Practice: Detection and Monitoring of ctDNA Using Structural Variants
13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
14:00 – 14:15 CET – Redefining the Standard in MRD: Structural Variants & Digital PCR for Ultra Sensitivity & High Specificity
Monday, October 26
13:00 – 13:15 CET- The Role of Longitudinal ctDNA Testing in Early and Advanced Stage Cancer
13:30 – 13:45 CET – Don’t Miss the Loss: Unlocking MTAP, PTEN & Others Through Robust Copy Number Detection
14:00 – 14:15 CET – HRD Signature Without Limits: Go Beyond Ovarian
To learn more, visit Foundation Medicine in person at booth 1030 in Hall 10 or book a meeting at View Source

Full List of Foundation Medicine’s Abstracts at ESMO (Free ESMO Whitepaper) Congress 2026

Presentation Number

Title

Product

Friday, October 23

2218RO

Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)

FoundationOneLiquid CDx

2219RO

Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)

FoundationOne Liquid CDx, FoundationOneMonitor

4294P

The Tumor-Agnostic (TA) Therapy Biomarker Landscape: Established and Emerging Markers Across 385,420 Solid Tumors

FoundationOneCDx

4304P

Comprehensive Genomic Profiling in Lacrimal Duct Carcinoma Reveals HER2-Driven Biology and Emerging Therapeutic Targets

FoundationOne CDx

4762P

Homologous Recombination Signature (HRDsig) in Adenocarcinoma (ACB) and Urachal Carcinoma (UrCA) of the Bladder: Implications for PARP Inhibitor (PARPi) Treatment

FoundationOne CDx

4308P

Genomic Landscape of KRAS G12D Mutant Non-Small Cell Lung Cancer (NSCLC) and Comparison with KRAS non-G12D Mutant and KRAS Wild Type Cases

FoundationOne CDx

4372P

MTAP Loss and HPV Status in Head and Neck Squamous Cell Carcinoma (HNSCC): A Genomic Landscape Study

FoundationOne CDx

2232P

Longitudinal ctDNA tumor fraction (TF) as a prognostic biomarker in bone-dominant metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 ± olaparib: Results from the phase 2 COMRADE trial

FoundationOne Liquid CDx,

FoundationOne Monitor

4750P

Overall survival (OS) and mature safety results of SURE-02, a phase 2 study of neoadjuvant Sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant Pembro, in patients with muscle-invasive bladder cancer (MIBC)

N/A

4283P

ctDNA tumor fraction captures tumor biology and predicts resistance to systemic therapy across solid tumors and NSCLC

FoundationOne Liquid CDx

Monday, October 26

3765P

Homologous Recombination Signature (HRDsig) in Angiosarcoma (AngSarc)

FoundationOne CDx

2628P

Genomic and Biomarker Landscape of MTAP loss/KRAS G12D mutant vs. MTAP loss/KRAS non-mutated Advanced NSCLC

FoundationOne CDx

(Press release, Foundation Medicine, OCT 21, 2026, View Source [SID1234673653])